Core Viewpoint - LeMaitre Vascular, Inc. (LMAT) shows potential as a stock pick due to a recent "golden cross" event and positive earnings expectations, indicating a bullish trend [1][4]. Technical Analysis - LMAT has recently experienced a "golden cross," where its 50-day simple moving average has crossed above its 200-day simple moving average, suggesting a potential bullish breakout [1][2]. - A golden cross typically follows a downtrend, indicating a reversal in price momentum, and is considered a strong bullish signal [3]. Performance Metrics - Over the past four weeks, LMAT's stock price has increased by 27.3%, reflecting strong upward momentum [4]. - The stock currently holds a 2 (Buy) rating on the Zacks Rank, further supporting the notion of a potential breakout [4]. Earnings Expectations - In the current quarter, there have been four upward revisions in earnings estimates for LMAT, with no downward changes, indicating positive sentiment among analysts [4]. - The Zacks Consensus Estimate for LMAT has also increased, reinforcing the bullish outlook for the stock [4]. Investment Consideration - Given the significant technical indicators and favorable earnings revisions, investors are encouraged to consider adding LMAT to their watchlist [6].

Company Overview - LeMaitre Vascular, Inc. (LMAT) is a leading owner-operator in the peripheral vascular device market with a market cap of $1.9 billion, designing and marketing over 100 specialized devices for vascular procedures outside the heart and brain [2] - The company has grown through a disciplined roll-up strategy, acquiring more than 30 subsidiaries, which allows it to leverage a fragmented market and achieve operational synergies [3] Financial Performance - LeMaitre has historically achieved revenue growth at a CAGR of 12–15% and EPS growth at a CAGR of 19–21%, with forward growth estimates remaining attractive [5] - The company enjoys a 71% gross margin, 21% return on invested capital (ROIC), and strong free cash flow conversion, indicating robust financial health [4] Competitive Advantage - LeMaitre benefits from a durable competitive advantage due to its highly specialized products, regulatory barriers, and strong relationships with surgeons [4] - The founder-led management under George W. LeMaitre aligns shareholder interests with long-term growth, having delivered over 1,500% returns since the 2006 IPO [3] Growth Drivers - The company has dual growth engines: organic demand driven by an aging global population and minimally invasive surgery trends, alongside inorganic growth through acquisitions [4] - Valuation metrics suggest reasonable upside, trading below its 10-year average forward P/E, with expected returns of 11–16% per year [5] Investment Thesis - LeMaitre Vascular exemplifies a high-quality, patient, and compounding business in a resilient and growing medical device niche, supported by strong fundamentals and disciplined capital allocation [5] - The Total Quality Score of 8/10 reflects its status as an exceptional investment opportunity [5]

Core Viewpoint - LeMaitre Vascular (NASDAQ: LMAT) has shown significant stock performance, with shares increasing approximately 35% since June 2025, outperforming the broader market by more than double [1]. Financial Performance - The stock experienced a notable jump of around 20% following a strong Q4 earnings report, which included an upward revision of expectations for 2026 [1].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 Registrant's telephone number, including area code 781-221-2266 | Securities registered under Section 12(b) of the Act: | | | ...

LMAT Investor Presentation Disclaimers Unaudited Financial Results The quarterly financial results in this document are unaudited. Large and Growing Global Sales Force Forward-Looking Statements This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward- looking statements. Factors that might cau ...

Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, a gross margin of 71.7%, and a 47% increase in operating income [4] - Q4 fully diluted earnings per share were $0.68, representing a 39% year-over-year increase [8] - For the full year 2025, organic revenue growth was 14%, with adjusted gross margin at 70.4% and adjusted EPS growth of 23% [9] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvetomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Autograft sales grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4][9] Market Data and Key Metrics Changes - EMEA region sales grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales of autograft are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The company plans to consolidate its Chicago RFA facility into Burlington in 2026 to simplify operations and reduce costs [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating 12% sales growth and 21% adjusted operating income growth [6][11] - The company experienced a cyber incident in January 2026 but reported minimal disruption to sales and manufacturing [9][10] Other Important Information - The board approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, marking the 15th consecutive year of dividend increases [10] - The company ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million [9] Q&A Session Summary Question: Can you rank the factors key to achieving operating growth? - Management highlighted stable headcount, sales pricing growth, and improved manufacturing efficiency as key factors for operating leverage [16] Question: What contributed to the smoother price transition this year? - Management noted that sending price lists earlier allowed for better preparation among sales and customer service teams, leading to a smoother transition [17] Question: What is the setup for M&A in 2026? - Management indicated a focus on organic growth but remains open to M&A opportunities, particularly in the open vascular area [28][30] Question: Can you elaborate on the performance of Artegraft? - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [33] Question: How is the company performing in China? - Management reported a 24% revenue increase in Q4, with profitability achieved for the first time in the region [47] Question: What is the outlook for gross margin in 2026? - Management expects gross margin to increase by 170 basis points from 2025 to 2026, driven by pricing increases and manufacturing efficiencies [75] Question: What is the anticipated impact of the Restore Flow manufacturing transfer? - Management indicated it may be a slight headwind to margins in 2026 as operations transition [96]

LeMaitre Vascular (NasdaqGM:LMAT) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsDanny Stauder - Director of Equity ResearchDave Roberts - PresidentDorian LeBlanc - CFOGeorge LeMaitre - CEORick Wise - Managing DirectorConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJim Sidoti - AnalystKyle Bauser - Managing Director and Senior Research AnalystMichael Petusky - Managing Director and Senior Investment AnalystMichael Sarcone - Equity AnalystNone - Analy ...

Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, with a gross margin of 71.7% and operating income growth of 47% [4] - Q4 fully diluted earnings per share were $0.68, a 39% increase year-over-year [9] - For the full year 2025, organic revenue growth was 14%, with adjusted gross margin at 70.4% and adjusted EPS growth of 23% [10] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvetomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Autograft sales grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4] Market Data and Key Metrics Changes - EMEA region sales grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales of autograft are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The 2026 U.S. price list reflects a blended 8% increase across the portfolio, with early results indicating hospital acceptance [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating revenue of $280 million, organic sales growth of 12%, and operating income of $77.8 million, up 21% adjusted from 2025 [12] - The company experienced a cyber incident in January 2026 but reported minimal disruption to sales and manufacturing [10][11] Other Important Information - The board approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, marking the 15th consecutive year of dividend increases [11] - The company ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million [10] Q&A Session Summary Question: Guidance and Operating Growth Factors - Management highlighted stable headcount, sales pricing growth, and manufacturing efficiencies as key factors for achieving operating growth above sales growth [15][16] Question: Price Increases and Future Outlook - Management noted that the smoother transition for price increases this year was due to earlier communication and preparation [18][19] Question: M&A Environment and Strategy - The company is actively pursuing M&A opportunities, focusing on open vascular and cardiac surgery markets, with 22 targets identified [30][32] Question: Artegraft Performance and Market Potential - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [34][35] Question: Impact of CREST-2 Trial on Carotid Business - Management stated that the carotid shunt business remains resilient and is transitioning to an OUS business model [70][72] Question: Gross Margin Outlook - Management expects continued gross margin improvement, with guidance for a 170 basis point increase from 2025 to 2026 [80][82] Question: Restore Flow Manufacturing Transfer - The transfer of Restore Flow manufacturing is expected to be a slight headwind to margins in 2026, with costs already included in guidance [102]

Exhibit 99.1 LeMaitre Q4 2025 Financial Results BURLINGTON, MA, February 25, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average sellin ...

Core Insights - LeMaitre Vascular, Inc. reported strong Q4 2025 results with a 16% increase in sales and a 47% increase in operating income, driven by growth in international markets and higher average selling prices [1][4][3] Financial Performance - Q4 2025 sales reached $64.5 million, a 16% increase compared to Q4 2024, with organic growth of 15% [9][22] - Gross margin improved to 71.7%, up 240 basis points, due to higher average selling prices and manufacturing efficiencies [3][9] - Operating income for Q4 was $18.8 million, reflecting a 47% increase, with operating expenses growing moderately by 6% [3][9] - Diluted EPS for Q4 was $0.68, a 39% increase year-over-year [21] Sales Growth Drivers - Key product categories contributing to sales growth included grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) [3] - Regional sales growth was notable, with EMEA sales increasing by 29%, APAC by 20%, and the Americas by 10% [3] Guidance and Future Outlook - For Q1 2026, the company expects sales between $65.6 million and $67.6 million, representing an 11% increase [4] - Full-year 2026 guidance anticipates sales of $280 million, a 12% increase, and operating income of $77.8 million, a 21% adjusted increase [4] - The company plans to maintain a gross margin of 72.1% for 2026 [4] Dividend and Share Repurchase - The Board of Directors approved a 25% increase in the quarterly dividend to $0.25 per share, payable on March 26, 2026 [6] - A share repurchase program was authorized for up to $100 million, set to conclude on February 18, 2027, unless extended [7]